Advertisement

Endocrine

pp 1–6 | Cite as

A cure model survival analysis of patients affected by small intestinal neuroendocrine neoplasms: the Bologna ENETS center experience

  • Claudio Ricci
  • Davide Campana
  • Chiara Casadei
  • Carlo Ingaldi
  • Valentina Ambrosini
  • Nico Pagano
  • Donatella Santini
  • Cristina Mosconi
  • Nicole Brighi
  • Laura Alberici
  • Francesco Minni
  • Riccardo CasadeiEmail author
Original Article
  • 56 Downloads

Abstracts

Purpose

The primary end-point was to evaluate the cure fraction. Secondary end-points were to investigate the time to cure, the excess of death risk, the probability of cure and the factors related to these parameters.

Methods

Retrospective study of an ENETS database regarding patients affected by Si-NENs. For each patients, clinical, pathological and follow-up data were collected. The survival analysis was made using a novel approach: the cure model approach.

Results

The cure fraction was 92.1%. The death risk, time to cure and the probability of cure were 6/1000 person-years, 3.6 years and 98.2%, respectively. The independent factors influencing these parameters were the grading and the R status (P = 0.041 and P = 0.017, respectively). Patients affected by Si-NENs G2 increased the death risk and time to cure respect to Si-NENs G1 (51 versus 6 per 1000 person-years and 5.1 versus 3.6 years, respectively) as well as patients not operated respect to those radically resected (R0/1) (66 versus 1 per 1000 person-years and 4.8 versus 0.4 years, respectively). The probability of cure decreased (88.1 versus 97.8% and 80.4 versus 99.7%, respectively). R2 resection shows better results than no resection.

Conclusions

A large portion of patients affected by Si-NENs can be cured. The highest probability of cure regards patients with Si-NENs G1 who underwent to R0/R1 resection; the lower, those with Si-NENs G2 and no resection. R2 resection seems to be preferred respect to no resection.

Keywords

Small intestine Neuroendocrine neoplasms Cure model 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

12020_2019_1870_MOESM1_ESM.tif (3 mb)
Supplementary figure.
12020_2019_1870_MOESM2_ESM.docx (16 kb)
Supplementary sMethods.
12020_2019_1870_MOESM3_ESM.docx (15 kb)
supplementary sResults.

References

  1. 1.
    A. Dasari, C. Shen, D. Halperin, B. Zhao, S. Zhou, Y. Xu, T. Shih, J.C. Yao, Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol.  https://doi.org/10.1001/jamaoncol.2017.0589
  2. 2.
    B. Niederle, U.F. Pape, F. Costa, D. Gross, F. Kelestimur, U. Knigge, K. Öberg, M. Pavel, A. Perren, C. Toumpanakis, J. O’Connor, D. O’Toole, E. Krenning, N. Reed, R. Kianmanesh. Vienna Consensus Conference participants ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 103, 125–138 (2016). all other Vienna Consensus Conference participantsCrossRefPubMedGoogle Scholar
  3. 3.
    L. Huang, K.A. Cronin, K.A. Johnson, A.B. Mariotto, E.J. Feuer. Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 112, 2289–2300 (2008)CrossRefPubMedGoogle Scholar
  4. 4.
    M. Cvancarova et al. Proportion cured models applied to 23 cancer sites in Norway. Int J. Cancer 132, 1700–1710 (2013)CrossRefPubMedGoogle Scholar
  5. 5.
    C. Ricci, R. Casadei, G. Taffurelli, D. Campana, V. Ambrosini, C.A. Pacilio, D. Santini, N. Brighi, F. Minni. Is radical surgery always curative in pancreatic neuroendocrine tumors? A cure model survival analysis. Pancreatology 18, 313–317 (2018)CrossRefPubMedGoogle Scholar
  6. 6.
    Italian population life tables. Available at: http://demo.istat.it/. Accessed 25 May 2018
  7. 7.
    P.C. Lambert, J.R. Thompson, C.L. Weston et al. Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8, 576–594 (2007)CrossRefPubMedGoogle Scholar
  8. 8.
    P.C. Lambert, Modeling of the cure fraction in survival studies. Stata J. 3, 1–25 (2007)Google Scholar
  9. 9.
    P. Tomassetti, D. Campana, L. Piscitelli, R. Casadei, F. Nori, E. Brocchi, D. Santini, R. Pezzilli, R. Corinaldesi. Endocrine tumors of the ileum: factors correlated with survival. Neuroendocrinology 8, 380–386 (2006)CrossRefGoogle Scholar
  10. 10.
    L. Wu, J. Fu, L. Wan, J. Pan, S. Lai, J. Zhong, D.C. Chung, L. Wang. Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget 8, 4935–4947 (2017)PubMedGoogle Scholar
  11. 11.
    I.M. Modlin, K.D. Lye, M. Kidd. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97, 934–959 (2003)CrossRefPubMedGoogle Scholar
  12. 12.
    K.Y. Bilimoria, D.J. Bentrem, J.D. Wayne, C.Y. Ko, C.L. Bennett, M.S. Talamonti. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann. Surg. 249, 63–71 (2009)CrossRefPubMedGoogle Scholar
  13. 13.
    G. Capurso, M. Rinzivillo, R. Bettini, L. Boninsegna, G. Delle Fave, M. Falconi. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br. J. Surg. 99, 1480–1487 (2012)CrossRefPubMedGoogle Scholar
  14. 14.
    E.A. Woltering, B.A. Voros, D.T. Beyer, Y.Z. Wang, R. Thiagarajan, P. Ryan, A. Wright, R.A. Ramirez, M.J. Ricks, J.P. Boudreaux. Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution. J. Am. Coll. Surg. 224, 434–447 (2017)CrossRefPubMedGoogle Scholar
  15. 15.
    E. Bertani, M. Falconi, C. Grana, E. Botteri, A. Chiappa, P. Misitano, F. Spada, D. Ravizza, B. Bazolli, N. Fazio. Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. Int. J. Surg. 20, 58–64 (2015)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Claudio Ricci
    • 1
  • Davide Campana
    • 1
  • Chiara Casadei
    • 1
  • Carlo Ingaldi
    • 1
  • Valentina Ambrosini
    • 2
  • Nico Pagano
    • 1
  • Donatella Santini
    • 2
  • Cristina Mosconi
    • 2
  • Nicole Brighi
    • 2
  • Laura Alberici
    • 1
  • Francesco Minni
    • 1
  • Riccardo Casadei
    • 1
    Email author
  1. 1.Department of Internal Medicine and Surgery (DIMEC), Alma Mater StudiorumUniversity of Bologna, S.Orsola-Malpighi HospitalBolognaItaly
  2. 2.Department of Haematology and Oncology (DIMES), Alma Mater StudiorumUniversity of Bologna, S.Orsola-Malpighi HospitalBolognaItaly

Personalised recommendations